Manufacturers of 48 Medicare Part B drugs raised their prices faster than inflation in the last quarter of 2023 — in some cases even in each quarter over the past year — and the drugmakers will now face stiff penalties under the year-old Inflation Reduction Act (IRA), the White House said.
Source: Drug Industry Daily